Year: 2024
Type: editorial
Abstract: The oncolytic virotherapy BT-001 (Transgene and BioInvent) with the PD-1 inhibitor pembrolizumab (Keytruda, Merck) was safe and replicated in the tumors of six patients with solid tumors who had fa...
Authors: Ronald Ellis, Adam Weiss
Institution: Taylor and Francis (United Kingdom)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,175
OpenAlex ID: W4403460820